Livalo and Pomalyst drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Livalo (pitavastatin calcium) and Pomalyst (pomalidomide). Common drug interactions include plasma cell myeloma among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Livalo and Pomalyst. It is created by eHealthMe based on reports of 43 people who take the same drugs from the FDA, and is updated regularly.

What is Livalo?

Livalo has active ingredients of pitavastatin calcium. It is often used in high blood cholesterol. eHealthMe is studying from 8,802 Livalo users. Check the latest studies of Livalo.

What is Pomalyst?

Pomalyst has active ingredients of pomalidomide. eHealthMe is studying from 80,400 Pomalyst users. Check the latest studies of Pomalyst.



On Jul, 09, 2026

43 people who take Livalo and Pomalyst together, and have interactions are studied.

Livalo and Pomalyst drug interactions.

What are the common drug interactions of Livalo and Pomalyst, by gender? *:

female:

  1. Plasma cell myeloma (cancer that begins in plasma cells)
  2. Pyrexia (fever)
  3. Palpitations (feelings or sensations that your heart is pounding or racing)
  4. Abdominal discomfort
  5. Anaemia (lack of blood)
  6. Back pain
  7. Blepharitis (chronic inflammation of the eyelid)
  8. Blood creatinine increased
  9. Blood urea increased
  10. Bone pain

male:

  1. Fatigue (feeling of tiredness)
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Dyskinesia (abnormality or impairment of voluntary movement)
  4. Neuropathy peripheral (surface nerve damage)
  5. Rash erythematous (redness of the skin)
  6. Somnolence (a state of near-sleep, a strong desire for sleep)
  7. Back pain
  8. Dyspepsia (indigestion)
  9. Dysphonia (speech disorder attributable to a disorder of phonation)
  10. Pain

What are the common drug interactions of Livalo and Pomalyst, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Plasma cell myeloma (cancer that begins in plasma cells)
  2. Back pain
  3. Enterocolitis (inflammation of the digestive tract, involving enteritis of the small intestine and colitis of the colon)
  4. Epistaxis (bleed from the nose)
  5. Fatigue (feeling of tiredness)
  6. Hypercalcaemia (elevated calcium (ca+) level in the blood)
  7. Leukopenia (less number of white blood cells in blood)
  8. Lip dry
  9. Lymphocyte count decreased
  10. Micturition disorder (disease of passing urine)

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 43 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Livalo and Pomalyst?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Livalo and Pomalyst:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Livalo:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Pomalyst:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Livalo and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Pomalyst and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on pitavastatin calcium and pomalidomide (the active ingredients of Livalo and Pomalyst, respectively), and Livalo and Pomalyst (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: